Inactive Instrument

Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Biotechnology & Medical Research

Gracell Biotechnology Ltd Appoints Kevin Xie as Chief Financial Officer

July 23, 2020 at 10:00 am EDT

Gracell Biotechnologies Co. Ltd. has announced appointment Chief Financial Officer Kevin Xie, PhD, MBA . Along with CEO Dr. William Cao, Dr. Sersch and Dr. Xie joined Gracell in their respective functions to support the company's mission of providing novel cellular therapies for unmet medical needs. CFO Dr. Kevin Xie came to Gracell with extensive healthcare finance and investment experience in leadership positions. Prior to Gracell, Dr. Xie was most recently the President of Fosun Healthcare Holdings and Chief Representative of Fosun in New York.

Latest news about Gracell Biotechnologies Inc.

Global markets live: Booking, Diageo, AT&T, Nvidia, UBS...	Feb. 23
EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"	Feb. 22	AN
AstraZeneca Completes Gracell Biotechnologies Acquisition	Feb. 22	MT
Stifel Downgrades Gracell Biotechnologies to Hold From Buy, Trims Price Target to $10.25 From $11	Feb. 22	MT
AstraZeneca completes acquisition of Gracell Biotechnologies	Feb. 22	CF
AstraZeneca Closes Purchase of Gracell Biotechnologies	Feb. 22	MT
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index	Feb. 21	CI
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. from a group of shareholders.	Feb. 21	CI
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Biotechnology Index	Feb. 20	CI
Gracell Biotechnologies Cleared for Early-Stage Trial of Prospective Multiple Myeloma Treatment	Jan. 29	MT
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T Gc012F as Early-Line Treatment of Multiple Myeloma	Jan. 29	CI
AstraZeneca to Buy China’s Gracell For $1.2 Billion	Dec. 27	MT
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says	Dec. 27	MT
Stocks start week higher as 2024 draws to close	Dec. 27	AN
Wells Fargo Downgrades Gracell Biotechnologies to Equalweight From Overweight, $10 Price Target	Dec. 27	MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15	Dec. 27	DP
Stocks hold onto gains amid US rate cut hopes	Dec. 27	AN
European Midday Briefing : Falling U.S. Inflation Continues to Support Sentiment	Dec. 27	DJ
Year-end rate-cut optimism, miners push UK stocks higher	Dec. 27	RE
FTSE 100 gains led by miners and industrials	Dec. 27	AN
AstraZeneca buys Gracell to "enrich" cell therapy pipeline	Dec. 27	AN
AstraZeneca: agreement to acquire Gracell	Dec. 27	CF
AstraZeneca buys Gracell Biotech; COPL CEO resigns	Dec. 27	AN
Piper Sandler Downgrades Gracell Biotechnologies to Neutral From Overweight, Raises Price Target to $10 From $9	Dec. 27	MT
EMEA Morning Briefing : Stock Futures Higher to Start Last Trading Week of Year	Dec. 27	DJ

Chart Gracell Biotechnologies Inc.

Duration

Period

More charts

Company Profile

Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+56.06%	55.7B
LONZA GROUP AG	+41.08%	39.91B
IQVIA HOLDINGS INC.	-5.58%	39.57B
CELLTRION, INC.	-5.56%	28.16B
ICON PUBLIC LIMITED COMPANY	+16.39%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-20.51%	18.94B
MEDPACE HOLDINGS, INC.	+32.93%	12.17B
UNITED THERAPEUTICS CORPORATION	+26.00%	12.12B
BIO-TECHNE CORPORATION	+2.60%	12.12B

Other Biotechnology & Medical Research